scholarly journals A novel embryonic plasticity gene signature that predicts metastatic competence and clinical outcome

2015 ◽  
Vol 5 (1) ◽  
Author(s):  
Rama Soundararajan ◽  
Anurag N. Paranjape ◽  
Valentin Barsan ◽  
Jeffrey T. Chang ◽  
Sendurai A. Mani
Keyword(s):  
Clinical Outcome ◽  
Gene Signature

scholarly journals A stemness-related seven-gene signature for predicting prognosis and treatment response in muscle invasive bladder cancer

2020 ◽  
Author(s):  
Maolang Tian ◽  
Jinlan He ◽  
Jiaqi Han ◽  
Hong Zhu
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Clinical Outcome ◽  
Treatment Response ◽  
Risk Score ◽  
Gene Signature ◽  
Invasive Bladder Cancer ◽  
Cancer Stemness ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

Abstract Background: Muscle invasive bladder cancer (MIBC) is an aggressive cancer characterized by therapeutic resistance and poor prognosis, which are possibly due to the existence of cancer stem cells (CSCs). In this study, we aimed to characterize the expression of cancer stemness-related genes and develop a multi-gene risk signature to predict clinical outcome and treatment response in MIBC.Methods: The mRNA expression data and clinical data of MIBC patients were collected from The Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO) database, which included the TCGA training cohort (n = 333) and three GEO validation cohorts, GSE13507 (n = 165), GSE32548 (n = 127), and GSE48075 (n = 72). A list of 166 stemness-related genes were obtained from the Cancer Single Cell State Atlas (CancerSEA) database and prognostic genes for overall survival (OS) were identified by univariate Cox analysis. Then, the least absolute shrinkage and selection operator (LASSO) regression and stepwise multivariate Cox regression were performed to generate a multi-gene risk signature. Kaplan-Meier curve, time-dependent receiver operating characteristic (ROC) curve, multivariate analysis, and stratification analysis were used to evaluate the performance of the gene signature. We also explored the relationship between risk score and response to chemotherapy and radiotherapy in MIBC patients. Moreover, independent prognostic factors for OS were combined together into a nomogram to improve predictive performance.Results: Firstly, a total of 25 prognostic genes were identified. Then, a seven-gene risk signature (EGFR, FOXA2, HES1, MME, RBM6, SMOC2, and TFRC) was constructed and it could robustly classify MIBC patients into high -risk and low-risk groups with different clinical outcomes. ROC curves showed that the seven-gene signature had a robust predictive accuracy in four cohorts. Besides, high risk score was significantly associated with advanced clinical stage and treatment failure. As an independent risk factor for OS, the stemness-related seven-gene signature could achieve better prognostic accuracy when integrated with clinical factors. Conclusions: We developed and validated a robust stemness-related gene signature which could robustly predicate clinical outcome and shed light on the cancer stemness in bladder cancer.

Interrogation ofERGgene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome

2013 ◽  
Vol 113 (2) ◽  
pp. 309-319 ◽  
Author(s):  
Tarek A. Bismar ◽  
Mohammed Alshalalfa ◽  
Lars F. Petersen ◽  
Liang Hong Teng ◽  
Travis Gerke ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Outcome ◽  
Gene Signature ◽  
Relevant Implication

scholarly journals Gene signature based on B cell predicts clinical outcome of radiotherapy and immunotherapy for patients with lung adenocarcinoma

2020 ◽  
Vol 9 (24) ◽  
pp. 9581-9594
Author(s):  
Linzhi Han ◽  
Hongjie Shi ◽  
Yuan Luo ◽  
Wenjie Sun ◽  
Shuying Li ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Lung Adenocarcinoma ◽  
B Cell ◽  
Gene Signature

Association of neuroendocrine (NE) mRNA expression profiling in hormone-sensitive tumors samples with adverse clinical outcome in castration-resistant prostate cancer (CRPC) patients.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 165-165
Author(s):  
Mayra Orrillo ◽  
Natalia Jimenez ◽  
Oscar Reig ◽  
Giancarlo Castellano ◽  
Albert Font ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Outcome ◽  
Treatment Strategies ◽  
Gene Signature ◽  
Molecular Profile ◽  
Castration Resistant Prostate Cancer ◽  
Adverse Clinical Outcome ◽  
Related Gene ◽  
Primary Tumors ◽  
Hormone Sensitive

165 Background: NE dedifferentiation is associated to clinical aggressiveness and resistance to androgen receptor inhibition in prostate cancer. We investigated impact of a NE expression signature in the clinical outcome of mCRPC patients treated with taxanes. Methods: This is a multicenter retrospective study. A customized panel of 45 NE-related gene signature was tested in total RNA from formalin-fixed paraffin-embedded hormone-sensitive tumor samples, by the nCounter platform (Nanostring Technologies). Patients were grouped according to their molecular profile by unsupervised clustering. Expression levels were correlated with taxanes response and clinical outcome. Independent association with survival was evaluated by multivariate Cox modeling. Results: Eighty seven patients were included in the study, 79 were treated with docetaxel and 8 with cabazitaxel. Median age was 64.8 (44-88.3) years and median follow-up was 20.7 (1.17-74.4) months. High expression of the NE signature was associated with a shorter time of CRPC development (N=60, median 12.8 vs 21.6, HR 2.4, 95%CI 1.3-4.3, P=0.003) and shorter OS from CRPC diagnosis (median 24.1 vs 41.33, HR 2.3, 95%CI 1.4-3.8, P=0.001). Moreover, according to the outcome to taxanes, high NE signature correlated with lower PSA-PFS (median 6.6 vs 10.1 mo P=0.047, HR 1.6, 95%CI 1-2.7, P=0.05) and OS (median 19 vs 22 mo, HR 1.8, 95%CI 1.1-2.8, P=0.014), and it was independently associated to a lower OS (HR 1.9, 95%CI 1.1-3.2, P=0.016). Conclusions: NE-related gene expression in hormone-sensitive tumor samples is associated with adverse clinical outcome and lower taxane benefit in metastatic CRPC patients. Thus, molecular characterization of primary tumors may be useful to guide treatment strategies in metastatic prostate cancer.

Abstract 1511: Stromal gene signature regulated by TGFβ signaling predicts poor clinical outcome in ovarian cancer .

2013 ◽  
Author(s):  
Dong-Joo Cheon ◽  
Yunguang Tong ◽  
Myung-Shin Sim ◽  
Xiaojiang Cui ◽  
Dror Berel ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Outcome ◽  
Gene Signature ◽  
Tgfβ Signaling ◽  
Poor Clinical Outcome
Sign in / Sign up

Export Citation Format

Share Document